Menassie Taddese, a newly appointed director of Xeris Biopharma Holdings, Inc., filed an initial statement of beneficial ownership with the SEC on November 4, 2026, disclosing no securities held as of the event date of November 2, 2026.

Key Highlights

  • Reporting person: Taddese Menassie, identified as a Director of Xeris Biopharma Holdings, Inc.
  • Event date: November 2, 2026, is listed as the date of the event requiring the statement.
  • No securities held: The filing states "No securities are beneficially owned" in both Table I (non-derivative) and Table II (derivative) sections.
  • Issuer and trading symbol: Xeris Biopharma Holdings, Inc., trading on NASDAQ:XERS.
  • Signed by attorney-in-fact: The filing was executed by Beth Hecht as attorney-in-fact on November 4, 2026, under an attached power of attorney.

Taddese Menassie Joins Xeris Biopharma Board With No Initial Share Position

According to the filing, Taddese Menassie submitted this initial statement of beneficial ownership in connection with becoming a director of Xeris Biopharma Holdings, Inc., a biopharmaceutical company whose shares trade under the ticker NASDAQ:XERS. The triggering event is recorded as November 2, 2026, two days before the filing date of November 4, 2026. The statement was filed individually, as a single reporting person, rather than as part of a joint or group filing.

The filing reports no holdings in any class of securities. Both Table I, covering non-derivative securities such as common stock, and Table II, covering derivative securities such as options, warrants, and convertible instruments, are left blank. The document explicitly confirms this with the notation "No securities are beneficially owned." Because this is an initial statement rather than a transaction report, no purchase price, share quantity, or acquisition date appears in the filing.

Beth Hecht signed the document as attorney-in-fact for Menassie, pursuant to Exhibit 24, a power of attorney attached to the filing. The filing was submitted individually and covers only Menassie's own beneficial ownership position at the time of the event.

What Was Disclosed

Xeris Biopharma Holdings, Inc. director Taddese Menassie filed an initial beneficial ownership statement dated November 2, 2026, reporting no direct or indirect holdings in any non-derivative or derivative securities of the company as of that date.